While trametinib, an FDA-approved targeted MEKi therapeutic for melanoma has improved the OS of patients with melanoma, most tumors with NRAS mutations are, at best, only partially responsive to MEKi-based therapy alone, and the development of resistance remains a challenge. This evidence concerns the gene NRAS and melanoma.